Stuart L. Goldberg

4.8k total citations
101 papers, 2.9k citations indexed

About

Stuart L. Goldberg is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Stuart L. Goldberg has authored 101 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Hematology, 46 papers in Genetics and 27 papers in Oncology. Recurrent topics in Stuart L. Goldberg's work include Chronic Myeloid Leukemia Treatments (47 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Eosinophilic Disorders and Syndromes (17 papers). Stuart L. Goldberg is often cited by papers focused on Chronic Myeloid Leukemia Treatments (47 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Eosinophilic Disorders and Syndromes (17 papers). Stuart L. Goldberg collaborates with scholars based in United States, Italy and Germany. Stuart L. Goldberg's co-authors include Andrew L. Pecora, Michele Baccarani, Timothy P. Hughes, Hagop M. Kantarjian, Andreas Hochhaus, Richard M. Stone, Francisco Cervantes, Rana Ezzeddine, Martin C. Müller and Jane F. Apperley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Stuart L. Goldberg

98 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart L. Goldberg United States	23	1.8k	1.4k	887	755	416	101	2.9k
Martine Gardembas France	21	1.9k 1.0×	1.7k 1.2×	1.1k 1.2×	394 0.5×	232 0.6×	64	2.6k
Paul La Rosée Germany	32	3.5k 1.9×	1.7k 1.3×	1.2k 1.4×	597 0.8×	733 1.8×	114	4.5k
A. Georgii Germany	30	1.3k 0.7×	1.4k 1.0×	523 0.6×	516 0.7×	575 1.4×	115	2.9k
Dale L. Bixby United States	27	1.6k 0.9×	864 0.6×	331 0.4×	756 1.0×	1.1k 2.8×	135	3.2k
Thoralf Lange Germany	32	3.0k 1.7×	1.4k 1.0×	693 0.8×	949 1.3×	483 1.2×	113	4.0k
Austin Kulasekararaj United Kingdom	35	3.3k 1.8×	1.5k 1.1×	142 0.2×	579 0.8×	880 2.1×	207	5.1k
Nicolaas Schaap Netherlands	39	2.1k 1.2×	794 0.6×	230 0.3×	1.5k 1.9×	1.0k 2.4×	152	4.6k
A. John Barrett United States	43	3.9k 2.2×	825 0.6×	215 0.2×	1.7k 2.3×	824 2.0×	109	6.0k
Giuseppe Bandini Italy	29	2.4k 1.3×	795 0.6×	260 0.3×	797 1.1×	502 1.2×	134	3.4k
Francis Ayuk Germany	37	2.9k 1.6×	818 0.6×	276 0.3×	1.2k 1.5×	827 2.0×	164	3.9k

Countries citing papers authored by Stuart L. Goldberg

Since Specialization

Citations

This map shows the geographic impact of Stuart L. Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart L. Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart L. Goldberg more than expected).

Fields of papers citing papers by Stuart L. Goldberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart L. Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart L. Goldberg. The network helps show where Stuart L. Goldberg may publish in the future.

Co-authorship network of co-authors of Stuart L. Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart L. Goldberg. A scholar is included among the top collaborators of Stuart L. Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart L. Goldberg. Stuart L. Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mauro, Michael J., Rüdiger Hehlmann, Loretta A. Williams, et al.. (2025). Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY. Leukemia & lymphoma. 66(9). 1615–1624. 1 indexed citations

Fonseca, Aline Simoneti, Paolo Fadda, Ciaran Mannion, et al.. (2023). Deregulated miRNA Expression in Triple-Negative Breast Cancer of Ancestral Genomic-Characterized Latina Patients. International Journal of Molecular Sciences. 24(17). 13046–13046. 8 indexed citations

Richter, Joshua, Larysa Sanchez, Noa Biran, et al.. (2020). Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(3). e284–e289. 15 indexed citations

Hehlmann, Rüdiger, Jörge E. Cortes, Teresa Zyczynski, et al.. (2018). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology. 94(1). 46–54. 33 indexed citations

Feldman, Tatyana, Charles M. Farber, Claudio Faria, et al.. (2017). Treatment of Peripheral T-Cell Lymphoma in Community Settings. Clinical Lymphoma Myeloma & Leukemia. 17(6). 354–361. 4 indexed citations

Goldberg, Stuart L., Michael R. Savona, & Michael J. Mauro. (2017). Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 18(2). 98–105. 8 indexed citations

Gutierrez, Martin, Richard B. Lanman, Edward Licitra, et al.. (2017). Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Clinical Lung Cancer. 18(6). 651–659. 156 indexed citations

Goldberg, Stuart L., et al.. (2015). Patients with Chronic Myelogenous Leukemia May Not Want to Discontinue Tyrosine Kinase Inhibitor Therapy. Blood. 126(23). 1584–1584. 21 indexed citations

Goldberg, Stuart L.. (2015). Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities. Clinical Lymphoma Myeloma & Leukemia. 15(12). 711–714. 12 indexed citations

10.

Donato, Michèle L., David S. Siegel, David H. Vesole, et al.. (2014). The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 20(8). 1211–1216. 48 indexed citations

11.

Donato, Michèle L., Themba Nyirenda, David H. Vesole, et al.. (2013). Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL). Blood. 122(21). 4545–4545. 1 indexed citations

12.

Guérin, Annie, Lei Chen, Katherine Dea, Eric Q. Wu, & Stuart L. Goldberg. (2013). Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. Journal of Medical Economics. 17(2). 89–98. 23 indexed citations

13.

Cortes, Jörge E., Rüdiger Hehlmann, Carlo Gambacorti‐Passerini, et al.. (2013). Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY). Blood. 122(21). 4026–4026. 4 indexed citations

14.

Mato, Anthony R., Jakub Svoboda, Tatyana Feldman, et al.. (2011). Post‐treatment (not interim) positron emission tomography‐computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R‐HyperCVAD. Cancer. 118(14). 3565–3570. 37 indexed citations

15.

Larson, Richard A., Udomsak Bunworasate, Anna Turkina, et al.. (2011). Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,. Blood. 118(21). 3768–3768. 8 indexed citations

16.

Romaguera, Jorge, Luis Fayad, Peter McLaughlin, et al.. (2010). Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. British Journal of Haematology. 151(1). 47–53. 36 indexed citations

17.

Preti, Robert A., H M Lazarus, Jane N. Winter, et al.. (2001). Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer. Cytotherapy. 3(2). 85–95. 11 indexed citations

18.

Lazarus, HM, Jane N. Winter, Donald A. Berry, et al.. (2001). Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplantation. 27(12). 1245–1253. 4 indexed citations

19.

Mangan, Kenneth F., et al.. (1995). Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.. Journal of Clinical Oncology. 13(6). 1323–1327. 146 indexed citations

20.

Levin, Mark, et al.. (1995). Primary Breast Carcinoma of the Vulva: A Case Report and Review of the Literature. Gynecologic Oncology. 56(3). 448–451. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact